Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Landay

Showing results (71-80 of 222) with videos related to

Pageof 23
Sort By:
AIDS Research and Therapy|April 14, 2005
Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimenHeather A Baird, Andre J Marozsan, Michael M Lederman, et al.
AIDS (London, England)|February 6, 2009
GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapyJack T Stapleton, Kathryn Chaloner, Jingyang Zhang, et al.
Clinical and Vaccine Immunology : CVI|August 3, 2007
Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infectionRichard M Novak, Betty A Donoval, Parrie J Graham, et al.
AIDS Research and Human Retroviruses|February 5, 2008
Association of cells with natural killer (NK) and NKT immunophenotype with incident cancers in HIV-infected womenMarek J Nowicki, Cheryl Vigen, Wendy J Mack, et al.
Clinical Immunology (Orlando, Fla.)|October 6, 2007
Immunophenotypic alterations in acute and early HIV infectionLena Al-Harthi, Sam MaWhinney, Elizabeth Connick, et al.
Frontiers in Immunology|March 25, 2025
Plasma lipidomic alterations during pathogenic SIV infection with and without antiretroviral therapySindhuja Sivanandham, Ranjit Sivanandham, Cuiling Xu, et al.
AIDS (London, England)|June 5, 2007
Immune responses to abacavir in antigen-presenting cells from hypersensitive patientsAnnalise M Martin, Coral-Ann Almeida, Paul Cameron, et al.
AIDS Research and Human Retroviruses|January 24, 2012
Longitudinal assessment of pigtailed macaque lower genital tract microbiota by pyrosequencing reveals dissimilarity to the genital microbiota of healthy humansGregory T Spear, Ellen Kersh, Patricia Guenthner, et al.
The Journal of Infectious Diseases|June 27, 2022
Neutralizing Antibody Activity to Severe Acute Respiratory Syndrome Coronavirus 2 Delta (B.1.617.2) and Omicron (B.1.1.529) After 1 or 2 Doses of BNT162b2 Vaccine in Infection-Naive and Previously Infected IndividualsJames N Moy, Mark Anderson, Xiaoying Shen, et al.
AIDS (London, England)|January 27, 2007
Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cellsLivio Azzoni, Jihed Chehimi, Lan Zhou, et al.
Pageof 23

Showing results (71-80 of 222) with videos related to

Sort By:
Pageof 23
AIDS Research and Therapy|April 14, 2005
Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimenHeather A Baird, Andre J Marozsan, Michael M Lederman, et al.
AIDS (London, England)|February 6, 2009
GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapyJack T Stapleton, Kathryn Chaloner, Jingyang Zhang, et al.
Clinical and Vaccine Immunology : CVI|August 3, 2007
Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infectionRichard M Novak, Betty A Donoval, Parrie J Graham, et al.
AIDS Research and Human Retroviruses|February 5, 2008
Association of cells with natural killer (NK) and NKT immunophenotype with incident cancers in HIV-infected womenMarek J Nowicki, Cheryl Vigen, Wendy J Mack, et al.
Clinical Immunology (Orlando, Fla.)|October 6, 2007
Immunophenotypic alterations in acute and early HIV infectionLena Al-Harthi, Sam MaWhinney, Elizabeth Connick, et al.
Frontiers in Immunology|March 25, 2025
Plasma lipidomic alterations during pathogenic SIV infection with and without antiretroviral therapySindhuja Sivanandham, Ranjit Sivanandham, Cuiling Xu, et al.
AIDS (London, England)|June 5, 2007
Immune responses to abacavir in antigen-presenting cells from hypersensitive patientsAnnalise M Martin, Coral-Ann Almeida, Paul Cameron, et al.
AIDS Research and Human Retroviruses|January 24, 2012
Longitudinal assessment of pigtailed macaque lower genital tract microbiota by pyrosequencing reveals dissimilarity to the genital microbiota of healthy humansGregory T Spear, Ellen Kersh, Patricia Guenthner, et al.
The Journal of Infectious Diseases|June 27, 2022
Neutralizing Antibody Activity to Severe Acute Respiratory Syndrome Coronavirus 2 Delta (B.1.617.2) and Omicron (B.1.1.529) After 1 or 2 Doses of BNT162b2 Vaccine in Infection-Naive and Previously Infected IndividualsJames N Moy, Mark Anderson, Xiaoying Shen, et al.
AIDS (London, England)|January 27, 2007
Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cellsLivio Azzoni, Jihed Chehimi, Lan Zhou, et al.
Pageof 23